The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580
Open accessAbstract
Colony-stimulating-factor-1 (CSF-1) signaling through cFMS receptor kinase is increased in several diseases. To help investigate the role of cFMS kinase in disease, we identified GW2580, an orally bioavailable inhibitor of cFMS kinase. GW2580 completely inhibited human cFMS kinase in vitro at 0.06 μM and was inactive against 26 other kinases. GW2580 at 1 μM completely inhibited CSF-1-induced growth of mouse M-NFS-60 myeloid cells and human monocytes and completely inhibited bone degradation in cultures of human osteoclasts, rat calvaria, and rat fetal long bone. In contrast, GW2580 did not affect the growth of mouse NS0 lymphoblastoid cells, human endothelial cells, human fibroblasts, or five human tumor cell lines. GW2580 also did not affect lipopolysaccharide (LPS)-induced TNF, IL-6, and prostaglandin E2 production in freshly isolated human monocytes and mouse macrophages. After oral administration, GW2580 blocked the ability of exogenous CSF-1 to increase LPS-induced IL-6 production in mice, inhibited the growth of CSF-1-dependent M-NFS-60 tumor cells in the peritoneal cavity, and diminished the accumulation of macrophages in the peritoneal cavity after thioglycolate injection. Unexpectedly, GW2580 inhibited LPS-induced TNF production in mice, in contrast to effects on monocytes and macrophages in vitro. In conclusion, GW2580's selective inhibition of monocyte growth and bone degradation is consistent with cFMS kinase inhibition. The ability of GW2580 to chronically inhibit CSF-1 signaling through cFMS kinase in normal and tumor cells in vivo makes GW2580 a useful tool in assessing the role of cFMS kinase in normal and disease processes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy
Lin, E. Y., Nguyen, A. V., Russell, R. G., & Pollard, J. W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.727 · Cited by 1,594
Dai, X.-M., Ryan, G. R., Hapel, A. J., Dominguez, M. G., Russell, R. G., Kapp, S., Sylvestre, V., & Stanley, E. R. (2002) · Blood · doi:10.1182/blood.v99.1.111 · Cited by 1,184
Wiktor-Jedrzejczak, W., Bartocci, A., Ferrante, A. W., Ahmed-Ansari, A., Sell, K. W., Pollard, J. W., & Stanley, E. R. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.12.4828 · Cited by 1,031
CSF-1 regulation of the wandering macrophage: complexity in action
Pixley, F. J., & Stanley, E. R. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.09.016 · Cited by 807
Cited by
Elmore, M. R. P., Najafi, A. R., Koike, M. A., Dagher, N. N., Spangenberg, E. E., Rice, R. A., Kitazawa, M., Matusow, B., Nguyen, H., West, B. L., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.040 · Cited by 1,968
“…several selective CSF1R kinase inhibitors (PLX3397 [Artis et al., 2005], PLX647 [Zhang et al., 2013], Ki20227 [Ohno et al., 2006], and GW2580 [Conway et al., 2005], and the nonselective kinase inhibitor dasatinib) on EOC 20 cells grown with either LADMAC spent media or conventional media, to…”
BackgroundZhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324
Colony-stimulating factors in inflammation and autoimmunity
Hamilton, J. A. (2008) · Nature reviews. Immunology · doi:10.1038/nri2356 · Cited by 1,305
“In addition to ligand or receptor blockade, another possible therapeutic strategy for M-CSF neutralization is by oral therapy targeting the tyrosine-kinase activity of the M-CSF receptor, as is already being teste”
MethodMitchem, J. B., Brennan, D. J., Knolhoff, B. L., Belt, B. A., Zhu, Y., Sanford, D. E., Belaygorod, L., Carpenter, D., Collins, L., Piwnica-Worms, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2731 · Cited by 943
Discovery of a Cytokine and Its Receptor by Functional Screening of the Extracellular Proteome
Lin, H., Lee, E., Hestir, K., Leo, C., Huang, M., Bosch, E., Halenbeck, R., Wu, G., Zhou, A., Behrens, D., et al. (2008) · Science · doi:10.1126/science.1154370 · Cited by 817
Hume, D. A., & MacDonald, K. P. A. (2012) · Blood · doi:10.1182/blood-2011-09-379214 · Cited by 763
Kumar, V., Donthireddy, L., Marvel, D., Condamine, T., Wang, F., Lavilla-Alonso, S., Hashimoto, A., Vonteddu, P., Behera, R., Goins, M. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.005 · Cited by 653
Xu, J., Escamilla, J., Mok, S., David, J., Priceman, S., West, B., Bollag, G., McBride, W., & Wu, L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3981 · Cited by 569
Skelly, D. A., Squiers, G. T., McLellan, M. A., Bolisetty, M. T., Robson, P., Rosenthal, N. A., & Pinto, A. R. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.072 · Cited by 560
Myofibroblast proliferation and heterogeneity are supported by macrophages during skin repair
Shook, B. A., Wasko, R. R., Rivera-Gonzalez, G. C., Salazar-Gatzimas, E., López-Giráldez, F., Dash, B. C., Muñoz-Rojas, A. R., Aultman, K. D., Zwick, R. K., Lei, V., et al. (2018) · Science · doi:10.1126/science.aar2971 · Cited by 519
MacDonald, K. P. A., Palmer, J. S., Cronau, S., Seppanen, E., Olver, S., Raffelt, N. C., Kuns, R., Pettit, A. R., Clouston, A., Wainwright, B., et al. (2010) · Blood · doi:10.1182/blood-2010-02-266296 · Cited by 506
Blériot, C., Dupuis, T., Jouvion, G., Eberl, G., Disson, O., & Lecuit, M. (2015) · Immunity · doi:10.1016/j.immuni.2014.12.020 · Cited by 471
Regulation of Microglial Proliferation during Chronic Neurodegeneration
Gómez-Nicola, D., Fransen, N. L., Suzzi, S., & Perry, V. H. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4440-12.2013 · Cited by 407
Jenkins, S. J., Ruckerl, D., Thomas, G. D., Hewitson, J. P., Duncan, S., Brombacher, F., Maizels, R. M., Hume, D. A., & Allen, J. E. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121999 · Cited by 401
Comprehensive characterization of the Published Kinase Inhibitor Set
Elkins, J. M., Fedele, V., Szklarz, M., Abdul Azeez, K. R., Salah, E., Mikolajczyk, J., Romanov, S., Sepetov, N., Huang, X.-P., Roth, B. L., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3374 · Cited by 323
Priceman, S. J., Sung, J. L., Shaposhnik, Z., Burton, J. B., Torres-Collado, A. X., Moughon, D. L., Johnson, M., Lusis, A. J., Cohen, D. A., Iruela-Arispe, M. L., et al. (2010) · Blood · doi:10.1182/blood-2009-08-237412 · Cited by 356
MRI of Tumor-Associated Macrophages with Clinically Applicable Iron Oxide Nanoparticles
Daldrup-Link, H. E., Golovko, D., Ruffell, B., DeNardo, D. G., Castaneda, R., Ansari, C., Rao, J., Tikhomirov, G. A., Wendland, M. F., Corot, C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3420 · Cited by 300
Holtan, S. G., Creedon, D. J., Haluska, P., & Markovic, S. N. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60669-1 · Cited by 292
Luo, J., Elwood, F., Britschgi, M., Villeda, S., Zhang, H., Ding, Z., Zhu, L., Alabsi, H., Getachew, R., Narasimhan, R., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20120412 · Cited by 262
Doloff, J. C., Veiseh, O., Vegas, A. J., Tam, H. H., Farah, S., Ma, M., Li, J., Bader, A., Chiu, A., Sadraei, A., et al. (2017) · Nature Materials · doi:10.1038/nmat4866 · Cited by 283
Studying the mononuclear phagocyte system in the molecular age
Chow, A., Brown, B. D., & Merad, M. (2011) · Nature Reviews Immunology · doi:10.1038/nri3087 · Cited by 279
WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited
Boulter, L., Guest, R. V., Kendall, T. J., Wilson, D. H., Wojtacha, D., Robson, A. J., Ridgway, R. A., Samuel, K., Van Rooijen, N., Barry, S. T., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76452 · Cited by 278
Microglial cell loss after ischemic stroke favors brain neutrophil accumulation
Otxoa-de-Amezaga, A., Miró-Mur, F., Pedragosa, J., Gallizioli, M., Justicia, C., Gaja-Capdevila, N., Ruíz-Jaen, F., Salas-Perdomo, A., Bosch, A., Calvo, M., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1954-4 · Cited by 258
Targeting monocytes/macrophages in the treatment of rheumatoid arthritis
Davignon, J.-L., Hayder, M., Baron, M., Boyer, J.-F., Constantin, A., Apparailly, F., Poupot, R., & Cantagrel, A. (2013) · Rheumatology · doi:10.1093/rheumatology/kes304 · Cited by 209
Complement 5a stimulates macrophage polarization and contributes to tumor metastases of colon cancer
Piao, C., Zhang, W.-M., Li, T.-T., Zhang, C.-C., Qiu, S., Liu, Y., Liu, S., Jin, M., Jia, L.-X., Song, W.-C., et al. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.03.009 · Cited by 106
Pleiotropic effects of extended blockade of CSF1R signaling in adult mice
Sauter, K. A., Pridans, C., Sehgal, A., Tsai, Y. T., Bradford, B. M., Raza, S., Moffat, L., Gow, D. J., Beard, P. M., Mabbott, N. A., et al. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.2a0114-006r · Cited by 100
“Many different CSF1R kinase inhibitors have been tested on various mouse disease models with some effect on bone: JNJ-28312141 prevented tumorinduced osteoclastogenesis and bone erosion [35]; Ki20227 inhibited osteolytic bone destruction through the suppression of CSF1-induced OCL accumulation in vivo [36]; SU11248 ca…”
BackgroundTarale, P., & Alam, M. M. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-00958-4 · Cited by 26
Martin-Estebane, M., & Gomez-Nicola, D. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00149 · Cited by 25
Metadata
- Authors
- Conway, J. G., McDonald, B., Parham, J., Keith, B., Rusnak, D. W., Shaw, E., Jansen, M., Lin, P., Payne, A., Crosby, R. M., Johnson, J. H., Frick, L., Lin, M.-H. J., Depee, S., Tadepalli, S., Votta, B., James, I., Fuller, K., Chambers, T. J., Kull, F. C., Chamberlain, S. D., & Hutchins, J. T.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-10-25
- Volume
- 102
- Issue
- 44
- Pages
- 16078-16083
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1970264868
- Cited by
- 247
- References
- 4
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.